Apimeds Pharmaceuticals US, Inc. (APUS) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Apimeds Pharmaceuticals US, Inc. stock (APUS) is currently trading at $1.71. WallStSmart rates APUS as Sell.
- APUS PE ratio analysis and historical PE chart
- APUS PS ratio (Price-to-Sales) history and trend
- APUS intrinsic value — DCF, Graham Number, EPV models
- APUS stock price prediction 2025 2026 2027 2028 2029 2030
- APUS fair value vs current price
- APUS insider transactions and insider buying
- Is APUS undervalued or overvalued?
- Apimeds Pharmaceuticals US, Inc. financial analysis — revenue, earnings, cash flow
- APUS Piotroski F-Score and Altman Z-Score
- APUS analyst price target and Smart Rating
Apimeds Pharmaceuticals US, Inc.
📊 No data available
Try selecting a different time range
Smart Analysis
Apimeds Pharmaceuticals US, Inc. (APUS) · 3 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Concerns around market cap and institutional own.. Significant fundamental concerns warrant caution or avoidance.
Apimeds Pharmaceuticals US, Inc. (APUS) Key Strengths (0)
Apimeds Pharmaceuticals US, Inc. (APUS) Areas to Watch (3)
Very low institutional interest at 3.15%
Micro-cap company with very limited liquidity and high volatility
Premium pricing at 3.2x book value
Apimeds Pharmaceuticals US, Inc. (APUS) Detailed Analysis Report
Overall Assessment
This company scores 9/100 in our Smart Analysis, earning a F grade. Out of 3 metrics analyzed, 0 register as strengths (avg 0/10) while 3 fall into concern territory (avg 3.0/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
Limited fundamental strengths were identified. The bull case requires improvement in core metrics.
The Bear Case
The primary concerns are Institutional Own., Market Cap, Price/Book. Some valuation metrics including Price/Book (3.17) suggest expensive pricing.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Institutional Own. improves, as this is the primary drag on the overall score. Second, overall profitability trends. Third, top-line growth trajectory.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Institutional Own. and Market Cap are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
APUS Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
Compare APUS with Competitors
Top DRUG MANUFACTURERS - SPECIALTY & GENERIC stocks by market cap
Compare any two stocks →Insider Transactions
Loading insider activity...
About Apimeds Pharmaceuticals US, Inc.(APUS)
NYSE MKT
HEALTHCARE
DRUG MANUFACTURERS - SPECIALTY...
USA
Apimeds Pharmaceuticals US, Inc. is a clinical stage biopharmaceutical company in the United States. The company is headquartered in Hopewell, New Jersey.